Professor Anskar Leung Yu-hung is currently a Chair Professor and Li Shu Fan Medical Foundation Professor in Haematology,  Deputy Chairperson in the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine and the Chairperson of the Department of Medicine in HKU-SZH.  He graduated in 1996 with MBChB (Hons) and PhD from the Chinese University of Hong Kong and joined The University of Hong Kong as Clinical Assistant Professor in 1999.  He obtained his specialist qualification in Haematology and Haematological Oncology in 2003 and was promoted to Clinical Associate Professor and Clinical Professor in 2007 and 2012 respectively.  His research focuses on the pathogenesis, therapeutic development and clinical management of acute myeloid leukaemia (AML).  In the laboratory, he has developed transgenic zebrafish models of human myeloid diseases for the discovery of novel therapeutics.  He has published more than 190 peer reviewed articles.  At professional level, Professor Leung is currently the Honorary Consultant at Queen Mary Hospital, Hong Kong Sanatorium & Hospital and co-director, Haematology and Haematological Oncology Centre, Gleneagles Hospital Hong Kong.

1. Zheng LC, Wong KKW, Lam SSY, Leung GMK, Li C, Tong KW, Lam W, Zeng XY, Chan KC, Chan NN, Ng KL, Dang CC, Kwok TH, Tsui SP, Sharma R, Wong JWH, Leung SY, Leung AYH, Man CH. Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial. Nat Commun. 2026 Apr 6. Epub ahead of print.
2. Tu L, He F, Liew JM, Sin CF, Zheng L, Tsui SP, Miao X, Chan HY, Ma ACH, Zhang W, Zhang Y, Leung AYH, Sun X. asxl1 C-terminal truncation and SRSF2 mutation drive leukemogenesis via immune reprogramming. Leukemia. 2025 Dec;39(12):3047-3051. 
3. Ng NKL, Lam SSY, Zheng L, Liu X, Liang M, Ng L, Chan KC, Zhang CX, Tse RLS, Cheung AKL, Ip HW, Au CH, Ma ESK, Ng CT, Ni Y, Li RS, Ling GS, Leung SY, Javed A, Leung AYH. Mechanism of Initial Favorable Response to Decitabine in TP53-Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse. Clin Cancer Res. 2025 Jul 15;31(14):3048-3061. 
4. Man CH, Lam W, Dang CC, Zeng XY, Zheng LC, Chan NN, Ng NKL, Chan KC, Kwok TH, Ng TC, Leung WY, Huen M, Wong CC, So CWE, Dou Z, Goyama S, Bray MR, Mak TW, Leung AYH. Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML. Blood. 2023 Sep22 Epub ahead of print.  
5. Wang D, Zheng L, Cheng BYL, Sin CF, Li R, Tsui SP, Yi X, Ma ACH, He BL, Leung AYH, Sun X. Transgenic IDH2R172K  and IDH2R140Q zebrafish models recapitulated features of human acute myeloid leukemia. Oncogene. 2023;42(16):1272-1281.
6. Man CH, Zeng X, Lam W, Ng TCC, Kwok TH, Dang KCC, Leung TWY, Ng NKL, Lam SSY, Cher CY, Leung AYH. Regulation of proton partitioning in kinase activating acute myeloid leukemia and its therapeutic implication. Leukemia. 2022; 36(8): 1990-2001.  
7. Tsui SP, Ip HW, Saw NY, Zhang C, Cheung AK, Ng NK, Man CH, Lam SS, Tang WF, Lin CH, Cheng GH, Au CH, Ma ES, Chan TL, So JC, Ng MH, Cheng KC, Wong KF, Siu LP, Yip SF, Lin SY, Lau JS, Luk TH, Lee HK, Lau CK, Kho B, Sim JP, Kwong YL, Leung SY, Javed A, Leung AY.  Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults.  Blood Cancer J. 2020;10(10):104.
8. He BL, Yang N, Man CH, Ng NK, Cher CY, Leung HC, Kan LL, Cheng BY, Lam SS, Wang ML, Zhang CX, Kwok H, Cheng G, Sharma R, Ma AC, So CE, Kwong YL, Leung AY. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. EMBO Mol Med. 2020; 12(8):e12911.
9. Lam SY, Ho ES, He BL, Wong WW, Cher CY, Ng NK, Man CH, Gill H, Cheung AM, Ip HW, So CC, Temburini J, So CW, Ho DN, Au CH, Chan TL, Ma ES, Liang R, Kwong YL, Leung AY.  Homoharringtonine (omacetaxine mepessucinate) as an adjunct for FLT3-ITD acute myeloid leukemia.  Sci Transl Med 2016; 8(359): 359ra129.
10. Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, Gill H, Lie AK, Liang R, Wong KF, Siu LL, Tsui CS, So CC, Wong HW, Yip SF, Lee HK, Liu HS, Lau JS, Luk TH, Lau CK, Lin SY, Kwong YL, Leung AY. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. Blood Cancer J. 2016; 6(7): e442.  
11. Man CH, Fung TK, Wan H, Cher CY, Fan A, Ng N, Ho C, Wan TS, Tanaka T, So EC, Kwong YL, Leung AY. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. Blood. 2015; 125(25): 3928-3936.

2018: Outstanding Research Student Supervisor Award (HKU)
2017: Faculty Outstanding Researh Ouput Prize   
2016: Croucher Senior Medical Research Fellowships
2014: Li Shu Fan Medical Foundation Professorship in Haematology

1.  Health@InnoHK, Innovation and Technology Commission of the HKSAR

Project:Centre for Oncology and Immunology
Role:  Programme leader in haematologic malignancy
Year awarded: 2020 (5 years)
Amount(HKD): 501,000,000 (Total Funding Ceiling)

2. Theme-based Research Scheme (T12-702/20-N)

Towards personalized and innovative treatment for acute myeloid leukaemia
Year awarded: 2020 (5 years)
Amount (HKD): 46,667,000

3.  Health and Medical Research Fund (06172586)

Modelling TP53-mutated acute myeloid leukaemia in zebrafish - biological and therapeutic implications
Year awarded: 2019 (3 years)
Amount (HKD): 1,498,688

4.  General Research Fund (HKU17126117)

Follistatin as a novel target and biomarker for acute myeloid leukaemia (AML) carrying internal tandem duplication (ITD) of Fms-Like Tyrosine kinase 3 (FLT3).
Year awarded: 2017 (3 years)
Amount (HKD): 1,229,089

5.  Health and Medical Research Fund (04152326)

Targeting DNA damage and repair mechanism in FLT3-ITD acute myeloid leukaemia (AML) - a mechanistic and therapeutic study (3 years)
Year awarded: 2017 (3 years)
Amount (HKD): 1,200,000

6.  Croucher Senior Medical Research Fellowships

Develop a high throughput platform for personalized treatment of acute myeloid leukaemia
Year awarded: 2016 (3 years)
Amount (HKD): 4,288,400

• Research student supervision (completed):14 Ph.D.; 7 M.Phil.; 3 M.Res.Med.; 2 M.Med.Sc.
• Postdoctoral fellow / research assistant professor supervision (completed): 6
• Current research student under supervision: 2 Ph.D. students
• Current postdoctoral fellow / research assistant professor under supervision: 4